LETTER FROM ASIA-PACIFIC AND BEYOND

Letter from France

Key words: COVID-19, droplet, tuberculosis.

Whether Carl Flügge is a medical hero is no longer debated today (Fig. 1). However, he died in 1932 without a lavish ‘pantheon ceremony’. Dr Flügge discovered and demonstrated how droplets released when coughing, sneezing or just chatting are a vehicle for airborne contagious microbes. As a Koch’s Fellow, he succeeded in profoundly changing the way tuberculosis (TB) was and is managed in non-endemic countries. The promotion of both patients and healthcare workers’ protection was standardized and promoted which dramatically decreased post-surgical infections. In the country where the BCG (Bacille de Calmette et Guerin) vaccine was developed, the control of TB is currently organized through regional centres entitled ‘Centre de Lutte Anti-Tuberculeuse’ (CLAT), all connected to a national reference centre. This network efficiently keeps the epidemic under control by patient referral and promotion of prevention and screening in maternity clinics and specific communities. These centres secure patients’ follow-up and high levels of compliance to quarantine, social distancing, face mask use and adherence to TB medications. Furthermore, CLAT are dedicated to contact tracing around each case in concert with the policy maker (ARS, Agence Régionale de Santé) through the enforcement of mandatory individual case reporting. Indeed, delay before insidious symptoms onset are TB features deserving such organization.

It is clear that we did not transpose Flügge’s knowledge and this established strategy of TB control to better address coronavirus disease-19 (COVID-19). We definitely should ask why.

The science of face masks and self-protection are key behavioural measures to control airborne infections. These preventive behaviours are not naturally part of our proud Latin traits, which may explain the discrepancies observed in the COVID pandemic outcomes between northern and southern countries of Europe. The weeks of lockdown have contributed to reinforce the messages for self-protection, but teaching needs repetition and straightforward messages should be reinforced again and again.

How should healthcare providers integrate this pre-acquired knowledge?

A snapshot of our healthcare institutions during this pandemic turmoil shows nearly the opposite side of what Dr Flügge may have advised in his time.

Perhaps thinking of it as harmless background noise inherited from the romantic period (‘the romantic phthisis’), we forgot about the spread of TB as a white plague for various reasons. The relatively low incidence of TB, the availability of the efficient ‘French vaccine’ and the beliefs that treatments are efficient and the national resistance rates quite low contributed to attitudes that air-related spread could be more or less kept aside.

In our hospitals, double-bed rooms and collective air circuits are common in wards. Except in some cases, screening tests are poorly available and patient contact tracking is deemed useful for TB, but difficult to implement.

As chest physicians, we inherited a great deal from the long history of TB control and we can now compare the two pandemics. The main distinction is that severe acute TB is a rare occurrence in our Westernized country nowadays, even in poor areas and specific communities.

The comparison between COVID-19 and TB can be drawn from diagnosis to prevention, when at present immunization is seen as the ‘holy grail’ for improving COVID-19-related outcomes (Table 1).
Rapid point-of-care screening tests and efficient microbiological assays are shared unmet needs for both TB and COVID-19. The indirect assessment of cellular and humoral immunity is not completely established in both diseases. Imaging using high-resolution computed tomography (HRCT) scan, with typical features seen during the COVID pandemic may also be explored for TB in high-income countries, especially to discriminate between active and latent TB infection. Identifying clusters of infections, investigating around a proven case and screening for healthcare workers—the three pillars of the CLAT missions—are the currently recommended strategies accompanying the end of lockdown worldwide.

The future will tell if policy makers can take advantage of the established TB network to limit the spread of COVID-19 and other airborne agents, and to what extent such measures will also impact TB—by far a greater killer in the world. In our institution, COVID-19 funnels were successfully applied in building efficient highways and precluding dissemination of cases throughout the hospital. In this period of epidemic decline, remaining COVID-19 clusters are unsurprisingly linked with already identified regional TB clusters such as squats and all places of precarious collective housing, where social distancing and barriers are impossible to access or apply. Access to these more precarious populations requires specific know-how, which is perfectly mastered by those responsible for the fight against TB (CLAT) in their activities including contact tracing.

There should be review and clarification of the exact missions and roles these CLAT are given, what clinical and scientific expertise we are relying on and how cost-effective, hygiene-suitable facilities can be implemented in our healthcare system despite limited resources. Given the non-negligible probability of more respiratory infectious pandemics in the future, with increased population, precariousness, climate change, etc., a nationwide institutional introspection seems to be a high priority.

Jérémy Charriot, MD,1 Laurie Pahus, PharmD, PhD,2,3,4 Pascal Chanez, MD, PhD,2,4 Nicolas Nagot, MD, PhD,5 and Arnaud Bourdin, MD, PhD1

1Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France; 2Clinique des bronches allergies et sommeil, Aix Marseille Univ, APHM, Marseille, France; 3Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France; 4Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France; 5Pathogenesis and

### Table 1: Similarities and discrepancies between tuberculosis and COVID-19

|                           | Tuberculosis | COVID-19-related syndrome |
|---------------------------|--------------|----------------------------|
| **Specificity of clinical presentation** | Weak         | Weak                       |
| **Course**                | Sub-acute    | Acute                      |
| **Population**            | Low constant incidence | High acute outbreak       |
| **Deaths**                | 1 500 000 (2018) | 283 000 (from the beginning) |
| **Number of active recruiting clinical trials for vaccine** | 15           | 48                         |
| **Pathogen**              | Mycobacteria | RNA virus                  |
| **Spread**                | Air droplets | Air droplets               |
| **Imaging HRCT for screening** | Debated     | Debated1                   |
| **Samples for diagnostic test** | Sputum      | Nasopharyngeal             |
|                           | BAL          | Sputum                     |
|                           | Gastric aspirate | BAL                     |
|                           | Stool        | Stool                      |
|                           | Granulomas with necrosis in tissues | In development |
| **Serum screening**       | IGRA         | Elderly                     |
| **Risk factors**          | Immunosuppressed | Elderly                   |
|                           | Migrants     | Obese                      |
|                           | Specific communities | Co-morbid HP, diabetes |
| **Prevention**            | BCG vaccine  | Masks                      |
|                           | Masks        | Case-proven investigation  |
|                           | Case-proven investigation | Lockdown              |
|                           | Chemoprophylaxis | Quarantine               |

1Hope et al.1

BAL, broncho-alveolar lavage; BCG, Bacille de Calmette et Guerin; HP, high blood pressure; HRCT, high-resolution computed tomography; IGRA, Interferon Gamma Release Assay.
Disclosure statement: L.P. reports personal fees from GlaxoSmithKline, Astra Zeneca and Chiesi, outside the submitted work.

REFERENCES

1 Hope Md, Raptis CA, Shah A, Hammer MM, Henry TS, on behalf of 6 singatories. A role for CT in COVID-19? What data really tell us so far. The Lancet 2020; 395: 1189–90.

2 Bedford J, Farrar J, Ihekweazu C, Kang G, Koopmans M, Nkengasong J. A new twenty-first century science for effective epidemic response. Nature 2019; 575: 130–6.